Pelthos Therapeutics Inc. (PTHS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Pelthos Therapeutics Inc. (PTHS) has a cash flow conversion efficiency ratio of -0.161x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.25 Million) by net assets ($38.88 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Pelthos Therapeutics Inc. - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how Pelthos Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Pelthos Therapeutics Inc. balance sheet liabilities for a breakdown of total debt and financial obligations.
Pelthos Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pelthos Therapeutics Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shenzhen Nanshan Power Co Ltd
SHE:200037
|
-0.035x |
|
Vissem Electronics Co. Ltd
KQ:072950
|
0.023x |
|
Marks and Spencer Group PLC
LSE:MKS
|
0.032x |
|
Ecos India Mobility & Hospitality Ltd
NSE:ECOSMOBLTY
|
0.088x |
|
Indorama Synthetics Tbk
JK:INDR
|
0.014x |
|
Fortune Mate Indonesia Tbk
JK:FMII
|
-0.006x |
|
Dae Chang
KO:012800
|
-0.035x |
|
Actinogen Medical Ltd
AU:ACW
|
-0.507x |
Annual Cash Flow Conversion Efficiency for Pelthos Therapeutics Inc. (2021–2025)
The table below shows the annual cash flow conversion efficiency of Pelthos Therapeutics Inc. from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Pelthos Therapeutics Inc..
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $38.88 Million | $-22.59 Million | -0.581x | -127.22% |
| 2024-12-31 | $-2.71 Million | $-5.79 Million | 2.134x | +1302.03% |
| 2023-12-31 | $-6.44 Million | $-981.03K | 0.152x | -64.00% |
| 2022-12-31 | $-3.71 Million | $-1.57 Million | 0.423x | -2.32% |
| 2021-12-31 | $-3.68 Million | $-1.59 Million | 0.433x | -- |
About Pelthos Therapeutics Inc.
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus… Read more